FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof. Invention also relates to a pharmaceutical composition which inhibits the epidermal growth factor receptor (EGFR) based on said compound.
EFFECT: obtaining a novel compound and a pharmaceutical composition based thereon, which can be used in medicine for treating cancer, particularly non-small cell lung cancer.
7 cl, 1 tbl, 1 ex
(I)
| Title | Year | Author | Number |
|---|---|---|---|
| IMPURITIES | 2019 |
|
RU2800278C2 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| NEW PYRIMIDINE DERIVATIVE WITH AN EFFECT OF INHIBITING GROWTH OF CANCER CELLS AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2018 |
|
RU2744168C1 |
| EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
| SALTS OF A QUINAZOLINE DERIVATIVE AND A METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2720810C2 |
| INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2018 |
|
RU2786524C2 |
| NEW PYRIMIDINE DERIVATIVE SUBSTITUTED WITH DEUTERIUM AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2020 |
|
RU2811770C1 |
| COMPOUNDS | 2018 |
|
RU2774952C2 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | 2022 |
|
RU2821531C2 |
